Phase 2 N=4 Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BAL101553 — 70 mg/m²
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=144 Prevention Focused Home-Based Physical Therapy Utilizing Community Partnership Referrals
Fall · Risk Reduction
Primary: Number of Participants With Reported Falls — 37; 34; 29; 24 Participants
Phase 4 N=14 Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
Phase 3 N=565 Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
Open Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP — 21; 22.9; 20.2; 21.9 mmHg
Phase 1 N=33 A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers
Healthy Volunteers · Anti-Bacterial Agents · Methicillin-Resistant Staphylococcus Aureus
Primary: Safety and Tolerability Evaluation — 1; 6; 1; 3 Participants
Phase 1 N=18 NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
Prostate Cancer · Bladder Cancer · Non-small Cell Lung Cancer
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) and Number of Patients With Adverse Events — 0; 0; 0; 3 Participants
Phase 1 N=31 Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection
Respiratory Syncytial Virus Prophylaxis
Primary: Number of Subjects Reporting Adverse Events Through 30 Days After Dosing — 3; 5; 3; 6 Participants
N/A N=15 Implementing Behavioral Sleep Intervention in Urban Primary Care
Sleep Disturbance · Sleep Deprivation · Sleep
Primary: Number of Caregiver-child Participants Who Complete All Intervention Procedures Following Enrollment (Retention Rate) — 13; 2 Participants
N/A N=52 Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma
Glaucoma · Glaucoma, Open-Angle · Glaucoma, Neovascular
Primary: Intraocular Pressure (IOP) — 15.2 millimeters of mercury (mm Hg)
N/A N=236 Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
Meibomian Gland Dysfunction · Evaporative Dry Eye Disease
Primary: Least Squares Mean Change From Baseline in Meibomian Gland Score (MGS) at Month 12 — 17.4; 17.8 score on a scale
Phase 2 N=255 A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Schizophrenia · Alcohol Use Disorder
Primary: Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS) — 25; 29; 87; 88 Participants — p=0.746
Phase 2 N=30 Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
Colorectal Cancer
Primary: Median Progression Free Survival (mPFS) — 8.8 months
Phase 2 N=30 Subarachnoid Hemorrhage Recovery And Galantamine
Subarachnoid Hemorrhage
Primary: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug — 1; 1 Participants
Phase 3 N=1 Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
Hemophilia A
Primary: Change of the Median Factor VIII (FVIII) Activity — 4.1 IU/dL
N/A N=79 Improving Linkage to Health and Other Services for Veterans Leaving Incarceration
Linkage to Care · Homelessness · Substance Use Disorder
Primary: Substance Use Care — 37; 7 Participants